MeSH term | MeSH ID | Detail |
---|---|---|
Hypertension | D006973 | 115 associated lipids |
Insulin Resistance | D007333 | 99 associated lipids |
Tauroursodeoxycholic acid is a lipid of Sterol Lipids (ST) class. Tauroursodeoxycholic acid is associated with abnormalities such as Hyperglycemia, Obesity, Wiskott-Aldrich Syndrome, neurogenic hypertension and Cholestatic liver disease. The involved functions are known as Cell Death, Apoptosis, Homeostasis, Process and mRNA Expression. Tauroursodeoxycholic acid often locates in Body tissue, Endoplasmic Reticulum, Hepatic, Blood and Protoplasm. The associated genes with Tauroursodeoxycholic acid are Homologous Gene and Mutant Proteins. The related lipids are cholanic acid, taurolithocholic acid 3-sulfate, Sterols, 7-dehydrocholesterol and tauromuricholic acid. The related experimental models are Disease model.
To understand associated biological information of Tauroursodeoxycholic acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Tauroursodeoxycholic acid is suspected in Endothelial dysfunction, Hyperglycemia, Obesity, neurogenic hypertension, Cholestatic liver disease, Heart failure and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Tauroursodeoxycholic acid
MeSH term | MeSH ID | Detail |
---|---|---|
Hypertension | D006973 | 115 associated lipids |
Insulin Resistance | D007333 | 99 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Disease model are used in the study 'Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.' (Cortez LM et al., 2015).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Henzel K et al. | Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. | 2004 | Biochim. Biophys. Acta | pmid:14741743 |
Komichi D et al. | Unique inhibition of bile salt-induced apoptosis by lecithins and cytoprotective bile salts in immortalized mouse cholangiocytes. | 2003 | Dig. Dis. Sci. | pmid:14714619 |
Alpini G et al. | Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. | 2004 | Am. J. Physiol. Gastrointest. Liver Physiol. | pmid:14701718 |
Tessier E et al. | High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. | 2003 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:14643509 |
Häussinger D et al. | Cell volume and bile acid excretion. | 1992 | Biochem. J. | pmid:1463469 |
Liu Y et al. | Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. | 2003 | J. Clin. Invest. | pmid:14623915 |
Nakai T et al. | Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine-treated rat liver. | 1992 | Biochem. J. | pmid:1361125 |
Reinehr R et al. | Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. | 2003 | Gastroenterology | pmid:12949729 |
Schoemaker MH et al. | Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. | 2003 | J. Hepatol. | pmid:12873810 |
pmid:12825132 |